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Methods and Materials: We enrolled patients with a 6-month estimated life expec-
tancy and 1 to 10 brain metastases with a diameter of 3 cm at 5 cancer centers. Volu-
metric radiosurgery was delivered in 5 fractions with 98% target coverage, prescribed
as 95% of 50 Gy (47.5 Gy in 5 fractions) to the metastases with no margin and 95% of
40 Gy (38 Gy in 5 fractions) to their 2-mm planning target volumes, concurrent with
20 Gy to the whole brain planning target volume. The treatment was delivered
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ventional volumetric modu-
lated arc therapy-capable
linear accelerators. Volu-
metric radiosurgery pro-
duced long-term toxicity and
control of treated metastases
similar to that of published
reports of multiple-isocenter,
single-fraction radiosurgery.3 months. The primary endpoint was the 3-month objective response in the brain ac-
cording to the Response Evaluation Criteria in Solid Tumors, version 1.1. The prin-
cipal secondary endpoint was 1-year actuarial control of treated metastases.
Toxicities were graded using the Common Terminology Criteria for Adverse Events,
version 4.0. The present study is registered with ClinicalTrials.gov (clinicaltrials.gov
identifier NCT01046123).
Results: From July 2010 to May 2013, 60 patients underwent VRS with 47.5 Gy in 5
fractions for 12 metastases in the thalamus and basal ganglia (deep metastases) and
207 non-deep metastases. The median follow-up period was 30.5 months, and the me-
dian survival was 10.1 months. For the 43 patients assessable at 3 months, the objec-
tive response in the brain was 56%. The treated metastases were controlled in 88% of
patients at 1 year and 84% at 3 years. Overall survival did not differ for patients with 4
to 10 versus 1 to 3 metastases (hazard ratio 1.18, PZ.6). The crude incidence of se-
vere radionecrosis (grade 3-5) was 25% (3 of 12) per deep metastasis, 1.9% (4 of 219)
per non-deep metastasis, and 10% (6 of 60) per patient.
Conclusions: For non-deep brain metastases, 47.5 Gy in 5 fractions was tolerable. Volu-
metric radiosurgery was effective for long-term control of treated brain metastases.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The Radiation Therapy Oncology Group (RTOG) 9508
phase 3 study demonstrated a survival advantage for pa-
tients with a solitary brain metastasis when stereotactic
radiosurgery (SRS) was added to whole brain radiation
treatment (WBRT) (1). For all patient subgroups,
WBRT þ SRS preserved the Karnofsky performance status
(KPS) and reduced the corticosteroid requirements better
than did WBRT alone.
Phase 3 studies have established the benefits of SRS
with and without WBRT for patients with 1 to 4 brain
metastases (1-4). Historically, patients with more metasta-
ses were ineligible for these trials because of the long SRS
treatment times, measured in hours (5). When volumetric
modulated arc therapy (VMAT) first became available, re-
searchers recognized that it could deliver targeted, high-
dose radiation to multiple brain metastases within a few
minutes per treatment session (6, 7).
The American Association of Neurological Surgeons
and the Congress of Neurological Surgeons have defined
radiosurgery as high-precision treatment sessions of 5
fractions (8). We have used the term “volumetric radio-
surgery” (VRS) to describe the treatment of multiple brain
metastases simultaneously using VMAT.
The lack of an on-site radiosurgery unit has been asso-
ciated with the diminished use of radiosurgery for brain
metastases (9). Our intention was to make radiosurgery
more widely available for the treatment of multiple brain
metastases. We report a phase 2 study of VRS for 1 to 10
brain metastases using VMAT on conventional linear
accelerators.Methods and Materials
Patients
The eligibility criteria were age >18 years, metastatic non-
hematologic malignancy, magnetic resonance imaging
(MRI) findings of 1 to 10 brain metastases with a diameter of
3 cm, KPS score 70, and anticipated median survival of
6months. TheRTOG recursive partitioning analysis (RPA)
and graded prognostic assessment aided in the survival
estimation (10, 11). Patients with previous craniotomy and
patients with brainstem metastases were eligible if they had
1 unresected, non-brainstem metastasis. The exclusion
criteria were small cell carcinoma, germ cell tumor, solitary
brain metastasis without extracranial disease, craniotomy
required to relievemass effect, pregnancy,multiple sclerosis,
glomerular filtration rate <60 mL/min, bilirubin or liver
transaminases more than twice the normal upper limit, pre-
vious cranial radiation therapy, targeted therapy or chemo-
therapy required within 1 week of treatment, and/or a total
volume of metastases >15 cm3. Every patient was approved
for enrollment by a multidisciplinary conference consisting
of radiation oncologists, neurosurgeons, and radiologists.
They triaged patients in RPA class 1 with 1 to 3 brain me-
tastases to SRS, not into the present study.Radiation therapy
For radiosurgery planning, the patients underwent a high-
resolution, 3-dimensional T1-weighted gadolinium-enhanced
MRI sequence, reconstructed every 0.9 to 1.0 mm. A
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prevent head rotation. A computed tomography scan with
intravenous contrast was performed for radiation therapy
planning using a slice reconstruction every 1.00 to 1.25 mm
and a field of view of 35 cm. The Eclipse treatment planning
system (Varian Medical Systems, Palo Alto, CA) was used to
co-register the MRI and computed tomography studies and to
segment the following structures: optics (optic chiasm and
optic nerves), brainstem, spinal cord, retinas, anterior cham-
bers, brain, andmetastases (Table 1). The segmented volumes
of the brain and brainstemmetastaseswere expanded by 2mm
to create the metastasis planning target volumes (PTVs) (7).
Skull metastases, if present, were added to the whole brain
clinical target volume,whichwas expanded by 2mm to create
awhole brain PTV. The structures underwent real-time review
before radiation therapy planning by a member of the study
committee.
The coverage of the target volumes was 98% (Table 1).
The VRS prescription for the brain metastases with no
margin was 95% of 50 Gy in 5 fractions (47.5 Gy in 5
fractions), which is radiobiologically similar to the sum of
the RTOG 9508 prescriptions of 37.5 Gy in 15 fractions
WBRT and 18 Gy in 1 fraction SRS (Table E1; available
online at www.redjournal.org) (12). Radiation therapy
planning of 47.5 Gy in 5 fractions to brain metastasesTable 1 Radiation therapy planning dose constraints for
volumetric radiosurgery and concurrent whole brain radiation
therapy
Structure
Dose constraints
Limit Volume Dose (Gy)
Anterior chambers
(no margin)
Upper <1% 10
Retinas (no margin) Upper <1% 25
Optics, PRV
(2-mm margin)
Upper <1% 25
Spinal cord, PRV
(2-mm margin)
Upper <1% 25
Brain metastasis
GTVs (no margin) Upper 0% 60 (120% of 50)
Lower 98% 47.5 (95% of 50)
PTVs (2-mm
margin)
Lower 98% 38 (95% of 40)
Shells around GTVs
(2-mm thickness)
Upper <5% 50
Normal brain
(brain  GTVs)
Upper <90 cm3 >25
Nonboosted brain
(brain  PTVs)
Upper <30 cm3 >30
Whole brain PTV
(2-mm margin)
Lower 98% 19 (95% of 20)
Brainstem metastasis
PTVs (2-mm
margin)
Upper 0% 40 (115% of 35)
Lower 98% 33.25 (95% of 35)
Abbreviations: GTV Z gross tumor volume; PRV Z planning risk
volume; PTV Z planning target volume.achieved coverage of their corresponding PTVs with 95%
of 40 Gy (38 Gy in 5 fractions). Figure E1 (available online
at www.redjournal.org) shows this dose profile. The VRS
prescription for the brainstem metastasis PTVs was 95% of
35 Gy (33.25 Gy in 5 fractions). The whole brain PTV
prescription was 20 Gy in 5 fractions, radiobiologically
similar to the prophylactic cranial irradiation prescription
of 25 Gy in 10 fractions WBRT (13).
The plans underwent pretreatment dosimetric quality
assurance. Treatment was delivered on 5 consecutive
working days with daily online translational setup correc-
tion using orthogonal kilovoltage imaging. Varian Clinac
iX or TrueBeam linear accelerators with 120-leaf collima-
tors (5 mm central leaf width) were used to deliver 2 axial
360 coplanar arcs at a dose rate of 600 MU/min, with the
collimator set at 30 to 45 for the clockwise arc and 330
to 315 for the anticlockwise arc. Dexamethasone 4 to
16 mg daily was prescribed during treatment and was either
stopped or tapered afterward.
Evaluations
The baseline patient assessments were history and physical
examination, KPS, and the Mini-Mental Status Examina-
tion. The follow-up examinations consisted of MRI every
3 months until 1 year and then imaging every 6 months,
with the same patient assessments as at baseline, plus
scoring of events that were possibly, probably, or definitely
related to treatment using the Common Terminology
Criteria for Adverse Events, version 4 (14). Toxicity from
radionecrosis was scored as follows: grade 1, imaging only;
grade 2, symptomatic; grade 3, disabling; grade 4, life-
threatening; and grade 5, death.
Statistical analysis
The primary endpoint was the brain objective response
according to the Response Evaluation Criteria in Solid
Tumors, version 1.1, at 3 months (15). The null hypothesis
was that the brain objective response would not be
significantly better than the brain objective response of
62% (48 of 78) for the WBRT arm of RTOG 9508 re-
ported by Andrews et al (their Table 9) (1). With an ex-
pected objective response of 80% to VRS, 1-sided PZ.05,
and power of 80%, the number of evaluable patients
required at 3 months was 39 (16). A sample size of 60
patients was selected with the anticipation of a 35%
incidence of no imaging at 3 months. The secondary
endpoints were the 1-year actuarial control of treated
metastases, the 1-year incidence of new metastases,
overall survival, toxicity, and cognition. The baseline
variables were compared using the c2 test, Fisher exact
test, and the median score test. Survival curves were
generated using the Kaplan-Meier method, and the log-
rank test was used for comparison. The time origin was
the consent date. To assess the effects of the prognostic
14 patients not enrolled because of 
metastases >3 cm (n = 5)
or more than 10 metastases (n = 9)
Treatment: started (n = 60), completed (n = 59)
Screened patients with 1-10 metastases on diagnostic CT (n = 157)
MRI to assess eligibility (n = 74)
Enrolled (n = 60)
All patients analysed (n = 60)
Lost to follow-up (n = 0)
Two patients  required a reduced 
dose of 45Gy/5 to meet normal 
tissue constraints
 
z
Fig. 1. Trial profile.
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confidence intervals were calculated using univariate and
multivariable Cox proportional hazards regression
models. The median follow-up duration was calculated
using the reverse Kaplan-Meier estimator. The cumulative
incidence used death as the competing event. Previous
research about the predictors of radionecrosis prompted
an exploratory multivariable logistic regression analysis
of the radionecrosis incidence stratified by the SRS
location (deep [basal ganglia and thalamus] vs non-deep
[not in the brainstem, basal ganglia, or thalamus]) and
target volume (17-19).
Treated metastases that met the Response Evaluation
Criteria in Solid Tumors for progressive disease were coded
as radionecrosis when confirmed by pathologic examina-
tion, low fluorodeoxyglucose tracer uptake on positron
emission tomography, or serial imaging showing enlarge-
ment followed by shrinkage without anticancer treatment
(20). Progressive disease was considered present if these
criteria for radionecrosis were not met. The imaging find-
ings of possible radionecrosis and progression events were
reviewed by the multidisciplinary conference team, and
controversial cases were referred to the data and safety
monitoring board. An intracranial cause of death was
assigned for either imaging or neurologic symptom pro-
gression before death.
The data were analyzed using Statistical Analysis Sys-
tems, version 9.3 (SAS Institute, Cary, NC). All analyses
used 2-tailed tests with an a of 0.05. The trial protocol and
consent forms were approved by the BC Cancer Agency
research ethics board. The trial was conducted according to
Canadian regulations and the International Conference on
HarmonizationeGood Clinical Practice (21). The study is
registered with ClinicalTrials.gov (clinicaltrials.gov iden-
tifier NCT01046123).Results
Patients
A total of 60 patients were enrolled from 5 cancer centers
in British Columbia, Canada from July 2010 to May 2013
(Fig. 1). The primary diagnoses were lung cancer in 53%,
breast cancer in 33%, and other cancer in 14% (Table 2). A
total of 219 metastases were in the brain and 4 were in the
brainstem. The mean number of brain metastases per pa-
tient was 3.7  2.7. Only 2 patients were RPA class 1
(<65 years old and without extracranial disease) (10). The
other 58 patients (97%) were RPA class 2. The median
interval from consent to treatment start was 9 days (inter-
quartile range 8-12). The overall treatment duration was 5
to 8 days. The mean treatment duration from the start of
setup imaging to the end of the last arc was
11.0  3.3 minutes for 1 to 3 metastases and
12.5  2.6 minutes for 4 to 10 metastases. The dosimetrydata are provided in Table E2 (available online at www
.redjournal.org) (22). One patient received only 4 frac-
tions because of extracranial disease progression. Two pa-
tients had minor planning protocol violations because they
required a reduced VRS prescription of 45 Gy in 5 fractions
to meet the nonboosted brain dose constraint. The data
from all 60 enrolled patients were analyzed by an intention-
to-treat for all outcomes.
Treated and new metastases
At 3 months, 43 of 49 living patients underwent brain
imaging studies. The primary study endpoint was consistent
with the null hypothesis, because the 56% (24 of 43)
objective response was not significantly better than 62% for
the WBRT arm of RTOG 9508. At 1 year, the treated me-
tastases were controlled in 88% of the patients. At 2 years,
the cumulative incidence was 14% for relapse of treated
metastases, 33% for new metastases, and 40% for all re-
lapses (Fig. 2A). The crude incidence of new metastases
was 33% (20 of 60). The 3-year cumulative incidence of
new metastases was 19% for those with 1 to 3 metastases
and 49% for those with 4 to 10 metastases (Fig. 2B).
Salvage treatment, given to 9 of the 60 patients (15%), was
SRS for 3 patients, repeat WBRT for 4, surgery for 1, and
both surgery and repeat WBRT for 1 patient.
Toxicity
Acute and late toxicities are presented in Table 3. The only
grade 3 acute toxicity was a case of somnolence syndrome.
One patient died of an unknown neurologic cause 4 weeks
after treatment andwas presumptively scored as having grade
5 acute radionecrosis. Whole brain radiation treatment
Table 2 Baseline clinical characteristics
Baseline variable
1-3 Metastases
(nZ32)
P value
(1-3 vs 4-10)
4-10 Metastases
(nZ28)
All patients
(nZ60)
Median age (y) 64 (37-83) .3 59 (35-81) 62 (35-83)
Median KPS score 90 (70-100) .6 90 (70-100) 90 (70-100)
Median MMSE score 29 (25-30) .07 30 (26-30) 29 (25-30)
Median number of metastases 2 (1-3) NA 5 (4-10) 3 (1-10)
Median diameter of largest metastasis (cm) 1.7 (0.6-2.6) .32 2.0 (1.0-3.1) 1.8 (0.6-3.1)
Median volume of all metastases (cm) 2.2 (0.2-8.6) .04 5.3 (0.7-12.6) 3.2 (0.2-12.6)
Age (y) .33
<65 19 (32) 20 (33) 39 (65)
65 13 (22) 8 (13) 21 (35)
Sex .76
Female 24 (40) 20 (33) 44 (73)
Male 8 (13) 8 (13) 16 (27)
KPS score .63
70-80 11 (18) 8 (14) 19 (32)
90-100 21 (35) 20 (33) 41 (68)
Extracranial metastases .09
Absent 9 (15) 3 (5) 12 (20)
Present 23 (38) 25 (42) 48 (80)
Primary resected .53
Yes 14 (23) 10 (17) 24 (40)
No 18 (30) 18 (30) 36 (60)
Neurologic symptoms 1.0
Yes 25 (42) 22 (37) 47 (79)
No 7 (11) 6 (10) 13 (21)
Histologic type .09
Lung 20 (33) 12 (20) 32 (53)
Breast 7 (12) 12 (20) 19 (32)
Melanoma 2 (3) 1 (2) 3 (5)
Rectum 2 (3) 0 (0) 2 (3)
Kidney 0 (0) 2 (3) 2 (3)
Anus 1 (2) 0 (0) 1 (2)
Esophagus 0 (0) 1 (2) 1 (2)
RPA (10)
Class 1 0 (0) 2 (3) 2 (3)
Class 2 32 (53) 26 (43) 58 (97)
DS-GPA (11) .09
0.0-1.0 3 (5) 10 (17) 13 (22)
1.5-2.0 11 (18) 6 (10) 17 (28)
2.5-3.0 14 (23) 8 (13) 22 (36)
3.5-4.0 4 (7) 4 (7) 8 (14)
Targeted therapy .35
No 27 (45) 20 (33) 47 (78)
Yes 5 (8) 8 (13) 13 (22)
Type of targeted therapy
Trastuzumab 4 (7) 4 (7) 8 (13)
Lapatinib 0 (0) 1 (2) 1 (2)
Erlotinib 1 (2) 0 (0) 1 (2)
Gefitinib 0 (0) 2 (3) 2 (3)
Sunitinib 0 (0) 1 (2) 1 (2)
Abbreviations: DS-GPA Z diagnosis-specific graded prognostic assessment; KPS Z Karnofsky performance status; MMSE Z Mini-Mental Status
Examination; RPA Z recursive partitioning analysis.
Data presented as median (range) or n (%).
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cerebrovascular disease: 1 developed cognitive impairment
due to radiation-induced leukoencephalopathy and 1, whohad received 20 Gy in 5 fractions to the optic nerves and
chiasm, developed radiation-induced optic neuropathy. In the
latter case, a retrospective review of the baseline imaging
P=.04
P=.01P=.05
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Fig. 2. (A) Cumulative incidence of relapse of treated metastases, relapse with new metastases, and all relapses in the brain.
(B) Cumulative incidence of new brain metastases for 1 to 3 versus 4 to 10 brain metastases. (C) Per-patient cumulative
incidence of toxicity from radionecrosis defined by the Common Terminology Criteria for Adverse Events, version 4.0 (grade
1, imaging only; grade 2, symptomatic; grade 3, disabling; grade 4, life-threatening; grade 5, death). Each curve displays the
earliest toxicity event in that grade group. (D) Per-metastasis cumulative incidence of toxicity from radionecrosis. (E) Overall
survival for patients with 1 to 3 versus 4 to 10 metastases. (F) Overall survival for patients treated with versus without
targeted therapy.
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chiasm. VRS caused grade 3 late toxicities in 3 patients
treated for deep brain metastases: 2 developed upper ex-
tremity hemiparesis (alive 14 and 29months afterward) and 1developed cognitive impairment due to thalamic injury
(survived 12 months afterward). Two patients required
craniotomy for grade 4 radionecrosis (survived 7 and
35 months afterward). The crude incidence of radionecrosis
Table 3 Toxicities graded using Common Terminology
Criteria for Adverse Events, version 4
Toxicity
Grade (n)
1 2 3 4 5
Acute
Headache 5 2 0 0 0
Nausea 10 2 0 0 0
Motor weakness 4 8 0 0 0
Seizure 0 1 0 0 0
Ataxia 4 0 1 0 0
Neuropathy, cranial 0 1 0 0 0
Vomiting 1 1 0 0 0
Radionecrosis 0 1 0 0 1
Somnolence 0 0 1 0 0
Worst acute toxicity per patient 14 12 1 0 1
Late
Headache 7 1 0 0 0
Nausea 0 1 0 0 0
Motor weakness 2 4 2 0 0
Seizure 0 0 0 0 0
Ataxia 0 3 0 0 0
Neuropathy, cranial 0 0 1 0 0
Vomiting 0 0 0 0 0
Radionecrosis 2 2 3 2 1
Neuropathy, optic 0 0 1 0 0
Cognitive impairment 0 0 2 0 0
Worst late toxicity per patient 6 5 5 2 1
Nichol et al. International Journal of Radiation Oncology  Biology  Physics318by patient was 10% (6 of 60) for grade 3 to 5 and 17% (10 of
60) for grade 1 to 5. The cumulative incidence of symptom-
atic radionecrosis (grade 2-5) was 13% at 3 years (Fig. 2C).
No patient received bevacizumab for radionecrosis (23).
The median volume of individual metastases was
0.4 cm3 (interquartile range 0.1-1.5, correspondingTable 4 Pretreatment clinical variables affecting survival
Factor
U
HR (95% CI
Targeted therapy (yes vs no) 0.45 (0.22-0.8
KPS score (70-80 vs 90-100) 1.59 (0.87-2.7
No. of metastases (2-10 vs 1) 1.56 (0.83-3.1
Extracranial disease status (present vs absent) 1.60 (0.83-3.4
Sex (male vs female) 2.20 (1.14-4.0
No. of metastases (4-10 vs 1-3) 1.18 (0.69-2.0
Largest metastasis diameter (greater than vs
less than median)
0.94 (0.54-1.6
Volume of all metastases (greater than vs less
than median)
1.30 (0.76-2.2
Primary disease status (present vs resected) 0.98 (0.56-1.6
Neurologic symptoms (yes vs no) 1.23 (0.65-2.5
Age (65 vs <65 y) 0.92 (0.52-1.6
Primary tumor category
Breast vs lung 0.84 (0.45-1.5
Other vs lung 0.96 (0.38-2.0
Abbreviations: CI Z confidence interval; HR Z hazard ratio.
* Multivariable model of clinical factors with P<.2 on univariate testing.diameter w0.9 cm). Grade 1-5 radionecrosis was observed
for 20 of 219 brain metastases (8.9%) and 0 of the 4
brainstem metastases (0%). It caused grade 2 or greater
symptoms in patients for 5.8% (13 of 223) of treated me-
tastases. After 47.5 Gy in 5 fractions for non-brainstem
metastases, the crude incidence of grade 1 to 5 radio-
necrosis was significantly greater for deep metastases
(thalamus and basal ganglia) at 25% (3 of 12) than for non-
deep metastases at 8.2% (17 of 207; odds ratio 4.0, 95%
confidence interval 1.02-15.73) and for the 12.1% (13 of
107) of metastases with volumes greater than the median at
12.1% (13 of 107) than for those with volumes less than or
equal to the median at 6.2% (7 of 112; odds ratio 3.2, 95%
confidence interval 1.3-8.1). For the 12 deep metastases, the
difference between the mean volume with radionecrosis
(1.5 cm3, range 0.4-2.5) and the mean volume without
radionecrosis (0.2 cm3, range 0.01-0.4) was large but not
significant (PZ.2). The crude incidence of grade 3 to 5
radionecrosis was 25% (3 of 12) per deep metastasis and
1.9% (4 of 219) per nondeep metastasis.
Survival
The median survival was 10.1 months (Fig. E2; available
online at www.redjournal.org). The cause of death was
extracranial progression in 44%, extracranial and intracra-
nial progression in 12%, intracranial progression in 24%,
and other in 10%. The baseline characteristics of the pa-
tients with 1 to 3 and 4 to 10 metastases were similar
(Table 2). On univariate analysis, the median survival of
patients with 1 to 3 versus 4 to 10 metastases did not differ
(Table 4, Fig. 2E). The pretreatment clinical variables with
P<.2 on univariate analysis were entered into a multivari-
able model that satisfied the proportional hazardsnivariate Multivariable*
) P value HR (95% CI) P value
3) .01 0.27 (0.13-0.54) .0004
9) .12 2.44 (1.29-4.49) .005
9) .19 2.09 (1.06-4.46) .04
0) .18 2.25 (1.13-4.95) .03
8) .02 1.68 (0.85-3.19) .12
3) .55
1) .81
6) .34
9) .93
1) .55
1) .78
.84
1)
8)
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to 80 versus 90 to 100, 2 to 10 metastases versus 1
metastasis, and the presence of extracranial disease. Longer
survival was predicted by the use of targeted therapy
(Table 3). The median survival was 19.3 months with, and
8.1 months without, targeted therapy (Fig. 2F).
Assessments
The median KPS score was 90 at baseline, 90 at 1 year
(nZ19), 75 at 2 years (nZ6), and 85 at 3 years (nZ2). The
median Mini-Mental Status Examination score was 29 at
baseline, 28 at 1 year (nZ18), 28 at 2 years (nZ2), and 29
at 3 years (nZ1). The percentage of patients requiring
corticosteroids was 57% (34 of 60) at baseline, 12% (5 of
43) at 3 months, 11% (2 of 18) at 1 year, 22% (2 of 9) at
2 years, and 50% (2 of 4) at 3 years.
Discussion
Whole brain radiation treatment halves the risk of the
development of new metastases without improving survival
and increases the incidence and severity of toxicity
compared with SRS alone (24). This led the American
Society for Radiation Oncology to issue a Choosing Wisely
recommendation on September 14, 2014: “Don’t routinely
add adjuvant whole brain radiation therapy to stereotactic
radiosurgery for limited brain metastases” (25). However, it
is technically straightforward to deliver VRS, first, with
concurrent prophylactic cranial irradiation-equivalent
WBRT, such as was used in the present study; second, with
concurrent hippocampal-sparing WBRT (26); or, third,
without any WBRT. Volumetric radiosurgery alone can be
delivered for 1 to 10 brain metastases simultaneously in one
12-minute fraction using a VMAT-capable radiosurgery
unit (5, 27) or in five 12-minute fractions using a VMAT-
capable conventional linear accelerator (28).
Concurrent 47.5 Gy in 5 fractions of VRS and adjuvant
20 Gy in 5 fractions of WBRT did not achieve a better
objective response in the brain at 3 months than that ach-
ieved with 37.5 Gy in 15 fractions in the WBRT arm in
RTOG 9508. In hindsight, we believe that we erred in
choosing a 3-month Objective Response as our study’s
primary endpoint, because radiosurgery is known to
be efficacious, unlike a novel systemic agent. A more
clinically relevant primary endpoint would have been
a comparison of the long-term control of treated brain
metastases using VRS and other techniques.
The principal secondary endpoint of our study was the
1-year control of treated metastases. We compared the
results for our 60 patients, with an average of 3.7 metas-
tases, with the results for the 331 patients in RTOG 9508,
with an average of 1.6 metastases (1). At 1 year of follow-
up, the percentage of patients with control of treated
metastases was 71% with WBRT, 82% with
WBRT þ SRS, and 88% with VRS. To investigate longerfollow-up data, we compared our study results with those
from the European Organization for Research and Treat-
ment of Cancer (EORTC) 22952 study, which randomized
patients treated with neurosurgery or 18 to 20 Gy in 1
fraction of SRS for 1 to 3 brain metastases to either
observation or adjuvant 30 Gy in 10 fractions of WBRT
(4). In the SRS cohort, 179 patients had an average of 1.4
metastases. At 2 years, the cumulative incidence of pro-
gression of treated metastases was 31% in the SRS-alone
subgroup, 19% in the SRS þ WBRT subgroup, and 16%
in our cohort treated with VRS In the JLGK0901 study,
1194 patients with 1 to 10 metastases, averaging 3.0 me-
tastases per patient, were treated with SRS alone (28). By
patient, the crude incidence of recurrence of the treated
metastases was 13% (138 of 1194) with SRS alone and
12% (7 of 60) with VRS in our study. Thus, despite the
potential for diminished dosimetric coverage of multiple
metastases from rotational setup errors around a single
isocenter, VRS achieved long-term control of treated
metastases similar to that achieved with multiple-
isocenter, single-fraction SRS (29).
We observed a greater incidence of radionecrosis per
patient than per metastasisdnot unexpected with 3.7
metastases per patient (Fig. 2C,D). By patient, the crude
incidence of grade 1 to 5 radionecrosis was similar between
the EORTC 22952 study and our study: 15% with
SRS þ WBRT versus 17% with VRS. In contrast, the
incidence of grade 3 to 5 radionecrosis was lower with
SRS þ WBRT (2%) than with VRS (10%) (4).
An increased risk of radionecrosis in the deep brain has
been reported with standard-dose SRS for arteriovenous
malformations and brain metastases (17, 18). We expected
47.5 Gy in 5 fractions to be well tolerated in all non-
brainstem regions. However, grade 3 radionecrosis devel-
oped around 3 deep brain metastases that were >0.4 cm3
and not around those that were <0.4 cm3. Therefore, we
recommend against prescribing 47.5 Gy in 5 fractions for
larger deep metastases.
Shorter survival was observed for those with 2 to 10
metastases compared with 1 metastasis but not for those
with 4 to 10 versus 1 to 3 metastases. This was in the
context of our multidisciplinary conference triaging the
best-prognosis patients with 1 to 3 metastases to SRS,
thereby limiting the enrollment of RPA class 1 patients to
only 3% of the study cohort. Our findings about the inter-
action between the number of treated metastases and sur-
vival echo those of the JLGK0901 study (28% RPA class
1), which found that survival was better with 1 metastasis
(13.9 months) but was the same with 2 to 4 versus 5 to 10
metastases (10.8 months) (28). We also observed that the
median survival was almost 1 year longer with the use of
targeted therapies.
The 2-year cumulative incidence of new metastases was
33% in our study and 33% in the SRS þ WBRT subgroup
of the EORTC 22952 study. This suggests that the 20 Gy in
5 fractions prophylactic cranial irradiation-equivalent
WBRT prescription is as effective as 30 Gy in 10
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the modern era of targeted therapy (4). For patients with 1
to 10 metastases, the crude incidence of new metastases
was 58% (625 of 1194) with SRS alone in the JLGK0901
study compared with 33% (20 of 60) with 20 Gy in 5
fractions of WBRT in our study (28).
Our ill-chosen primary endpoint was not the only study
limitation. First, formal neurocognitive testing was not
used. Second, instead of the orthogonal kilovoltage setup
imaging used in this study, cone beam computed tomog-
raphy is the current standard. Third, bevacizumab was not
accessible to patients requiring treatment of severe radio-
necrosis; thus, its reported incidence might not generalize
to centers at which bevacizumab is routinely used (23).
Fourth, only 16 brainstem and deep metastases were treated
in this study; thus, additional research is needed to deter-
mine the optimal 5-fraction radiosurgery prescription for
metastases in these locations.Conclusions
The VRS prescription of 47.5 Gy in 5 fractions to metas-
tases with no margin achieved control of treated metastases
that was similar to single-fraction SRS and was well
tolerated in the non-deep brain. However, we believed that
the risk of radionecrosis in deep brain metastases >0.4 cm3
was unacceptable. Thus, we would recommend treating
them with a lower dose. The present study showed that 5-
fraction VRS, which can be delivered using conventional
linear accelerators, is a convenient alternative to single-
fraction SRS for 1 to 10 brain metastases.References
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